Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Wael Harb, Mansoor N. Saleh, MD, Kyriakos P Papadopoulos, MD, Feng Chai, MD, Maria Larmar, Giovanni Abbadessa, MD, Brian Schwartz, MD, Anthony Tolcher, MD

Blood (2015) 126 (23): 5116.

https://doi.org/10.1182/blood.V126.23.5116.5116

Published: 2015

Journal Articles

Establishment and Characterization of a Patient-Derived Model of ALK-Positive Anaplastic Large Cell Lymphoma

Michael J Wick, PhD, Elena Helman, PhD, Teresa L Vaught, DVM, Monica Farley, BS, Drew W Rasco, MD, Lon Smith, MD, Anthony Tolcher, MD, Amita Patnaik, MD, Michael Clark, PhD, Kyriakos P Papadopoulos, MD

Blood (2015) 126 (23): 5121.

https://doi.org/10.1182/blood.V126.23.5121.5121

Published: 2015

Journal Articles

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

Niranjan S. Rao, PhD, Sanjeeva Reddy, PhD, Gupta Sandeep, PhD, Nitin K Damle, PhD, Venkatesan M Aranapakam, PhD, Scott Thompson, PhD, Roger Smith, PhD, Terry Plasse, MD, Penelope Bristow, MS, Anthony Tolcher, MD, Kyriakos P Papadopoulos, MD, Amita Patnaik, MD, Drew W Rasco, MD

Blood (2015) 126 (23): 4009.

https://doi.org/10.1182/blood.V126.23.4009.4009

Published: 2015

Journal Articles

A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible for or Have Previously Received an Autologous Stem Cell Transplant - Stage I Results.

Kyriakos P Papadopoulos, MD, Scott E. Smith, MD, PhD, Joyce Steinberg, MD, Renelle Papa, Javier Lopez-Jimenez, MD, Anne Keating, PharmD, Antoine Thyss

Blood (2012) 120 (21): 2731.

https://doi.org/10.1182/blood.V120.21.2731.2731

Published: 2012

Journal Articles

A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m 2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma

Ashraf Z. Badros, MD, Kyriakos P Papadopoulos, MD, Naseem Zojwalla, MD, Ju RueyJiuan Lee, PhD, David S. Siegel, MD, PhD

Blood (2012) 120 (21): 4036.

https://doi.org/10.1182/blood.V120.21.4036.4036

Published: 2012

Journal Articles

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m 2 Expansion Cohort of PX-171-007

Kyriakos P Papadopoulos, MD, Peter Lee, MD, PhD, Seema Singhal, MD, Joseph R. Holahan, MD, David H. Vesole, MD, PhD, Steven T. Rosen, MD, FRCPA, Lori Kunkel, MD, Alison L. Hannah, MD, David S. Siegel, MD, PhD

Blood (2011) 118 (21): 2930.

https://doi.org/10.1182/blood.V118.21.2930.2930

Published: 2011

Journal Articles

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

Kyriakos P Papadopoulos, MD, Pau Abrisqueta, MD, Glenda Chambers, BSN, RN, OCN, CCRC, Drew Rasco, MD, Amita Patnaik, Josep Tabernero, MD, Kanya Rajangam, MD, PhD, Kevin Rockich, Coumaran Egile, Adrianne Kelly, MD, Yi Xu, Joanne Lager, MD, Julie M Vose, MD

Blood (2011) 118 (21): 1608.

https://doi.org/10.1182/blood.V118.21.1608.1608

Published: 2011

NARROW

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Establishment and Characterization of a Patient-Derived Model of ALK-Positive Anaplastic Large Cell Lymphoma

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible for or Have Previously Received an Autologous Stem Cell Transplant - Stage I Results.

A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m 2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m 2 Expansion Cohort of PX-171-007

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Establishment and Characterization of a Patient-Derived Model of ALK-Positive Anaplastic Large Cell Lymphoma

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible for or Have Previously Received an Autologous Stem Cell Transplant - Stage I Results.

A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m 2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m 2 Expansion Cohort of PX-171-007

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only